亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

MISEV2023: An updated guide to EV research and applications

计算机科学 数据科学
作者
Joshua A Welsh,Deborah C. I. Goberdhan,Lorraine O’Driscoll,Clotilde Théry,Kenneth W. Witwer
出处
期刊:Journal of extracellular vesicles [Taylor & Francis]
卷期号:13 (2): e12416-e12416 被引量:97
标识
DOI:10.1002/jev2.12416
摘要

The publication of the new “Minimal Information for Studies of Extracellular Vesicles” (MISEV2023) (Welsh et al., 2024) is a high-water mark for the extracellular vesicle (EV) field. For the first time in the history of the International Society for Extracellular Vesicles (ISEV), a consensus document has been constructed with contributions from more than 1000 scientists. MISEV2023 addresses a wide range of the most pressing issues in the field, from nomenclature to in vivo studies, following on the MISEV2014 and MISEV2018 efforts (Lötvall et al., 2014; Théry et al., 2018). As the corresponding authors of the document, we would like to share our perspective on the outcome, the process behind it, and what this all means for the future of ISEV and MISEV. MISEV2023 has been written and revised to stand on its own as a guide to EV studies. Starting with an introduction with a historical perspective and ‘user guide’, MISEV2023 next takes the reader through all of the main aspects of an EV study. Community-sourced, it has something to offer beginners and veterans alike. The nomenclature section introduces the diversity of EVs and the need to avoid misusing the term ‘exosome’. It also highlights the ‘non-vesicular extracellular particles’ (NVEPs) that abound in most EV preparations. Collection and pre-processing underscores the importance of pre-analytical variables, with input on specific EV sources from ISEV task forces. EV separation and concentration and EV characterization have new details on key approaches. A new section on technique-specific reporting for EV characterization focuses on leading commercially available methods. EV release and uptake examines opportunities and pitfalls, while functional studies reminds us of important controls that are needed to help attribute an outcome to EVs. Finally, there is a new section on studying EVs in vivo. Despite the stand-alone nature of MISEV2023, it is nevertheless instructive to read and interpret this new document in the context of the previous MISEV publications, MISEV2014 and MISEV2018 (Lötvall et al., 2014; Théry et al., 2018). MISEV2014 was an editorial of the ISEV board, while MISEV2018 first gathered community input, with nearly 400 contributors. Interspersed with the previous MISEVs, numerous ISEV position papers, along with collaborative reviews and editorials, have guided the field in important ways. The ISEV position papers are summarized in Table 1 of MISEV2023. MISEV2023 began, as did MISEV2018, with a pre-drafting survey (Witwer et al., 2021). The input from this 2020 survey identified existing aspects to emphasize and new areas to explore. After reviewing the results of the survey, the ISEV board met at the end of 2020 and assigned a five-author committee (J.A. Welsh, D.C. Goberdhan, L. O'Driscoll, C. Théry and K.W. Witwer) to prepare a draft and guide the community input for the next MISEV. Numerous drafts and refinements were then prepared and shared with the ISEV board for feedback. Approximately 70 authors contributed to section drafts during this phase. Then, in 2022, an intermediate draft and a survey were shared with the ISEV community, resulting in >1000 responses. The three co-first authors worked hard and long to update MISEV based on this input. Multiple rounds of internal review and additional invited contributions/revisions ensued, along with style ‘unification’. In mid-2023, the article received pre-submission comments from JEV, followed by more revisions, formal submission, and three post-submission rounds of scrutiny (the first, main round including comments from more than 30 individuals). A near-final draft was shared with all co-authors for confirmation and a consensus survey. MISEV2023 was formally approved for publication by JEV on 13 December 2023. MISEV2023 has been a community effort like none other in the history of ISEV. Seventy-four scientists contributed original text and are listed on the ‘front page’ of the article as drafting authors. The final manuscript is published with 1051 co-authors, almost all of whom completed several extensive feedback questionnaires. According to primary affiliations, the authors represent at least 53 countries (Figure 1a, Table 1), with the top five including at least one country from each of the three geographical chapters of ISEV: the United States, Australia, Italy, the United Kingdom and France. The highest density of authors (per capita) was achieved by Slovenia, followed by Luxembourg, Sweden, Hungary and Australia (Figure 1b). The average author spent multiple hours completing the 2022 MISEV survey. Likewise, the average author spent more than two hours completing the 2023 authorship confirmation and consensus survey. We cannot possibly know the total amount of time that authors invested in MISEV2023, but we do know that, for most authors, the in-survey hours were accompanied by even more time spent reading and considering the manuscript before survey completion. Our debt of gratitude to the authors is tremendous. Among the many strengths of MISEV2023, there are also limitations. We acknowledge that MISEV is not and has never aimed to be a be-all and end-all document for EV research and translation. This is addressed in a dedicated introductory section ‘what MISEV “IS” and “IS NOT”’. Here, we clarify that MISEV should help build rigor and reproducibility and serve as a source of knowledge to help educate newcomers to the EV field. MISEV should not be an unreasonable barrier to entry, nor should it stifle innovation. While a number of sections focus on mammalian EVs, MISEV principles are generally relevant for EVs from all sources. We also highlight that MISEV is highly pertinent to translational and therapeutic applications: its approaches help to establish that a given biomarker or therapeutic outcome is actually associated with or facilitated by EVs. Similarly, MISEV is by no means a comprehensive review of the literature. As indicated in the introduction, not every one of the >500 citations in the paper is necessarily the first or the best paper to support the related statement. Most citations were suggested by the drafting topic experts, while others were added based on the community survey and reviewer comments. Compared with the first draft that was shared with the community in 2022, the published version of MISEV has around 200 added citations. Despite attempts to unify approaches, some MISEV sections have different citation density and perhaps even citation quality from others. Indeed, not all cited papers are necessarily consistent with the current guidelines. A citation is not endorsement of the approaches or conclusions of any study, and lack of citation also does not necessarily mean that a specific paper has been evaluated and rejected. We thank the community for their citation suggestions and apologize for any omissions and not doing full justice to the literature. At the time of the MISEV2014 editorial, it was still possible for an individual EV expert to maintain a reasonably comprehensive overview of the EV literature, which was limited to a few hundred key primary research publications. By MISEV2018, this situation had ended. Currently, thousands of EV publications appear each year, hence the challenge of categorizing their primacy and quality. MISEV is widely accepted and useful, but it is not perfect. Admittedly, a large portion of MISEV could be replaced by one statement: ‘Tell us exactly what you did’. We hope and trust, though, that the text going beyond this is nevertheless helpful for readers and not overly dogmatic. Every large scientific enterprise will have its detractors. But ultimately, most community members have been highly supportive of the MISEV process and product. We invite the remaining skeptics to follow the example of some of our harshest and most principled critics, who vociferously shared their viewpoints and objections, thereby helping make MISEV into a better document. Together, we can do better! Does doing better mean a future MISEV? MISEV2018 followed MISEV2014 by four years, and MISEV2023 has now been released another five years later. Will there be a need for another MISEV? The process of delivering MISEV has become complicated and lengthy, perhaps prohibitively so. MISEV2014 was essentially an editorial, written and published by a handful of scientists in a matter of months. MISEV2018 was more involved, introducing community engagement and taking a year from initial decisions to publication. MISEV2023 has been a much longer journey of three years. The full manuscript went through more than 30 distinct drafts. Despite the reward of the final outcome, would we have agreed to this assignment if we had known the true time commitment? In future, it may be difficult to expect any volunteer scientist to devote intensive, unpaid effort for three or more years to a project of this magnitude. Before any future iteration of MISEV, we would encourage careful evaluation of whether an update is truly needed, and, if so, a more structured approach to its construction. It may be more helpful for future guidelines to focus on specific methods, reagents, experimental design, or applications without a field-wide renewal of MISEV. These products could be led by ISEV task forces and special interest groups or ad hoc committees or collaborations with partner organizations. Perhaps MISEV could also be moved to a ‘living document’, such as a wiki-style approach, in which different parts can be updated as often and as intensively as thought necessary: a MISEV of the minute, not the half-decade. New tools, including artificial intelligence, if they continue to develop and are available for future MISEV-related initiatives, might be used to craft stronger consensus and, for example, better identify the ‘right’ citations than any human crowd-sourced document. Whatever is decided from the outset, our experience suggests that careful definition of the overall process and clear delegation of decision-making will be important. Starting with the pre-MISEV survey in 2020 and continuing today post-acceptance, more than 100 community members have volunteered to help spread the word about MISEV2023. Some scientists intend to write editorials or perspectives articles for journals they are familiar with. Others will reach out to journal editors and publishers to ensure that they are aware of MISEV2023. Several co-authors plan to feature MISEV2023 at a journal club or in a session at a scientific meeting, while others hope to contact regulatory entities or scientific societies. A press release has also been prepared. We are grateful for any and all assistance in bringing the value of MISEV to the widest audience possible and thereby elevating the entire EV community. In conclusion, we hope that the ultimate goal of MISEV will continue to be achieved: guiding the EV community to forge better understanding of basic biology and translate findings into benefits for human health and wider applications. Let us please take the opportunity to renew our commitment to this goal and to each other. Thank you for the opportunity to serve. It has been a pleasure to work with the vibrant EV community and coordinate our combined efforts into MISEV2023. The authors declare no conflicts of interest.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.4的应助被yoooooooo采纳,获得10
2秒前
momojee发布了新的文献求助10
3秒前
俏皮冰露发布了新的文献求助10
4秒前
希望天下0贩的0的应助被momojee采纳,获得10
9秒前
科研通AI6.2的应助被TannerPavent采纳,获得10
11秒前
12秒前
13秒前
魔幻诗兰发布了新的文献求助10
17秒前
yoooooooo发布了新的文献求助10
19秒前
20秒前
单纯寄云完成签到,获得积分10
21秒前
23秒前
23秒前
Yy发布了新的文献求助10
29秒前
TannerPavent发布了新的文献求助10
29秒前
zeki完成签到,获得积分20
30秒前
打打的应助被俏皮冰露采纳,获得10
33秒前
34秒前
科研通AI6.4的应助被yoooooooo采纳,获得10
43秒前
47秒前
49秒前
凶狠的映真完成签到,获得积分10
50秒前
俏皮冰露发布了新的文献求助10
52秒前
嘟嘟完成签到 ,获得积分10
54秒前
科研通AI6.2的应助被TannerPavent采纳,获得10
54秒前
1分钟前
yoooooooo发布了新的文献求助10
1分钟前
科研通AI6.4的应助被俏皮冰露采纳,获得10
1分钟前
缓慢芷文完成签到,获得积分10
1分钟前
TannerPavent发布了新的文献求助10
1分钟前
科研通AI6.2的应助被yoooooooo采纳,获得10
1分钟前
1分钟前
1分钟前
俏皮冰露发布了新的文献求助10
1分钟前
1分钟前
Ava的应助被cheng采纳,获得10
1分钟前
思源的应助被TannerPavent采纳,获得10
1分钟前
威武青寒完成签到,获得积分10
1分钟前
yoooooooo发布了新的文献求助10
1分钟前
SciGPT的应助被3sigma采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
CODESSA Version 2.13 for Windows 2000
Rosenblum, Global Change Biology 800
Berberine regulates the TLR4 signaling pathway to suppress hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells 520
Organizational Behavior 510
A Concise Course in Continuum Mechanics 400
A Silent Apostrophe:The Fayum Portraits 350
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 有机化学 化学工程 内科学 物理 生物化学 复合材料 催化作用 细胞生物学 人工智能 心理学 无机化学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 7846883
求助须知:如何正确求助?哪些是违规求助? 9367161
关于积分的说明 20653364
捐赠科研通 7443559
什么是DOI,文献DOI怎么找? 3341955
关于科研通互助平台的介绍 2485758
邀请新用户注册赠送积分活动 2364721